Just before leaving Washington for the Memorial Day recess in May, Congress approved legislation to enhance the ability of hospitals and public health agencies to respond to bioterrorist threats. A key addition to the bill reauthorizes the Prescription Drug User Fee Act (PDUFA) for 5 years so that the Food and Drug Administration will continue to accelerate development and approval of new drugs.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Congress expands drug safety surveillance as part of bioterrorism bill

Newsletter